Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 5, 2013, Pages 1239-1245

  Choo, Richard ^a   Lukka, Himu ^b   Cheung, Patrick ^c   Corbett, Tom ^b   Briones Urbina, Rosario ^d   Vieth, Reinhold ^e   Ehrlich, Lisa ^f   Kiss, Alex ^e   Danjoux, Cyril ^c  

^a MAYO CLINIC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT TREATMENT; ANDROGEN DEPRIVATION THERAPY; BONE MINERAL DENSITY; DUAL ENERGY X-RAY ABSORPTIOMETRY; METHODS AND MATERIALS; PROSTATE CANCERS; PROSTATE CARCINOMA; RANDOMIZED TRIAL;

DISEASES; LIGHT ABSORPTION; RADIOTHERAPY;

BIOMARKERS;

PLACEBO; RISEDRONIC ACID;

ADULT; AGED; ALLERGY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLEEDING; BLOATING; BONE DENSITY; BONE DISEASE; CANCER PATIENT; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; ESOPHAGITIS; FATIGUE; FLATULENCE; FOLLOW UP; GASTRITIS; GYNECOMASTIA; HOT FLUSH; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OSTEOLYSIS; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SWEATING; TREATMENT DURATION; UROGENITAL TRACT DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMUR; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBO EFFECT; PROSTATIC NEOPLASMS;

EID: 84875245132     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.11.007     Document Type: Article

References (20)

1. M.R. Smith, F.J. McGovern, and A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
2. J.F. Maillefert, J. Sibilia, and F. Michel Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 161 1999 1219 1222
3. V.B. Shahinian, Y.-F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
4. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897 7903
5. H.W. Daniell, S.R. Dunn, and D.W. Ferguson Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2000 181 186
6. E. Orwoll, M. Ettinger, and S. Weiss Alendronate for the treatment of osteoporosis in men N Engl J Med 343 2000 604 610
7. M.D. Michaelson, D.S. Kaufman, and H. Lee Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 2007 1038 1042
8. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
9. P. Taxel, R. Dowsett, and L. Richter Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer BJU Int 106 2010 1473 1476
10. K. Ishizaka, T. Machida, and S. Kobayashi Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer Int J Urol 14 2007 1071 1075
11. K. Izumi, A. Mizokami, and K. Sugimoto Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy Urology 73 2009 1342 1346
12. C.W. Ryan, D. Huo, and K. Bylow Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid BJU Int 100 2007 70 75
13. R.S. Israeli, S.J. Rosenberg, and D.R. Saltzstein The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy Clin Genitourin Cancer 5 2007 271 277
14. S.L. Greenspan, J.B. Nelson, and D.L. Trump Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial [Summary for patients in Ann Intern Med. 2007 Mar 20;146(6):I72; PMID: 17371883] Ann Int Med 146 2007 416 424
15. J. Planas, E. Trilla, and C. Raventós Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis BJU Int 104 2009 1637 1640
16. T.H. Diamond, J. Winters, and A. Smith The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study Cancer 92 2001 1444 1450
17. M.R. Smith, M.A. Fallon, and H. Lee Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial J Clin Endocrinol Metab 89 2004 3841 3846
18. M.R. Smith, R.A. Morton, and K.G. Barnette Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J Urol 184 2010 1316 1321
19. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
20. F.H. Yoon, S.L. Gardner, and C. Danjoux Testosterone recovery after prolonged androgen suppression in patients with prostate cancer J Urol 180 2008 1438 1443 discussion 1443-1444